Fig. 2: CP2 treatment restores cognitive function in symptomatic APP/PS1 mice. | Communications Biology

Fig. 2: CP2 treatment restores cognitive function in symptomatic APP/PS1 mice.

From: Partial inhibition of mitochondrial complex I ameliorates Alzheimer’s disease pathology and cognition in APP/PS1 female mice

Fig. 2

a Timeline of chronic CP2 treatment. b Weight of NTG and APP/PS1 mice treated with vehicle or CP2 through the duration of the study. c–h CP2 treatment improves a performance in the Morris Water Maze (c, d) and in the Novel Object Recognition test (e), reduces hyperactivity of APP/PS1 mice in the open field (f), and increases motor strength and coordination on the rotating rod (g) and hanging bar (h). NTG, n = 16 mice per group; NTG + CP2, n = 20 mice per group; APP/PS1, n = 21 mice per group; APP/PS1 + CP2, n = 19 mice per group. Data are presented as mean ± S.E.M. Data were analyzed by two-way ANOVA with Fisher’s LSD post-hoc test. A paired Student t-test was used for statistical analysis of NOR test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Body weight data in b were analyzed by linear regression analysis: Linear regression indicates that slopes between NTG (R squared = 0.6821) and NTG + CP2 (R squared = 0.9181) are different (P = 0.0234); slopes between APP/PS1 (R squared = 0.04326) and APP/PS1 + CP2 (R squared = 0.7668) are different (P < 0.0001); slopes between NTG (R squared = 0.6821) and APP/PS1 (R squared = 0.04326) are different (P = 0.0005). In all graphs: APP/PS1, orange line; NTG, black line; NTG + CP2, blue line; APP/PS + CP2, red line.

Back to article page